DNA topoisomerase I content of a pair of human melanoma cell lines with very different radiosensitivities correlates with their in vitro sensitivities to camptothecin

Anticancer Research

Volumn 18, Issue 4 C, 1998, Pages 3119-3126

  Ng, Cheng E ^a   Cybulski, Sheryl E ^a   Bussey, Alexandra M ^a   Aubin, Remy A ^b   Raaphorst, G Peter ^a  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

^b Sir FG Banting Research Centre   (Canada)

Author keywords

Camptothecin; DNA topoisomerase; Melanoma; Topoisomerase I

Indexed keywords

CAMPTOTHECIN; CELL DNA; DNA TOPOISOMERASE;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DNA SUPERCOILING; DRUG ACCUMULATION; DRUG SENSITIVITY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MELANOMA CELL; PRIORITY JOURNAL; RADIOSENSITIVITY;

ADULT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL TRANSPORT; CAMPTOTHECIN; CELL DIVISION; DNA TOPOISOMERASES, TYPE I; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; MALE; MELANOMA; RADIATION TOLERANCE; TUMOR CELLS, CULTURED;

EID: 0031868753     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Liu LF: Topoisomerases poisons as antitumor drugs. Ann Rev Biochem 58: 351-375, 1989.
2. Pommier Y, Kerrigan D, Hartman KD, et al: Phosphorylation of DNA topoisomerase I and activation by protein kinase C. J Biol Chem 265: 9418-9422, 1990.
3. Withoff S, de Jong S, de Vries EGE, Mulder NH: Human DNA Topoisomerase II: Biochemistry and Role in Chemotherapy Resistance (Review). Anticancer Research 16: 1867-1880, 1996.
4. Musk SRR, Steel GG: The inhibition of cellular recovery in human tumor cells by inhibitors of topoisomerase. Brit J Cancer 62: 364-367, 1990.
5. Giocanti N, Hennequin C, Balosso J, Mahler M, et al: DNA repair and cell cycle interactions in radiation sensitization by the topoisomerase II poison etoposide. Cancer Res 53: 2105-2111, 1993.
6. Ng CE, Bussey AM, Raaphorst GP: Inhibition of potentially lethal and sublethal damage repair by camptothecin and etoposide in human melanoma cell lines. Int J Rad Biol 66: 49-57, 1994.
7. Slichenmyer WJ, Rowinsky EK, Donehower RC, Kaufman SH: The current status of camptothecin analogues as antitumor agents. JNCI 85: 271-291, 1993.
8. Potmesil M, Pinedo HE, Potmesil M and Pinedo H, editors. Camptothecins: New anticancer agents. Boca Raton: CRC Press; 1995;
9. Giovanella BC, Stehlin JS, Wall ME, Wani MC, Nicholas AW, Liu LF, Silber R, Potmesil M: DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 246: 1046-1048, 1989.
10. Holden JA, Rolfson DH, Wiltwer CT: Human DNA topoisomerase II: Evaluation of enzyme activity in normal and neoplastic tissues. Biochem 29: 2127-2134, 1990.
11. Husain I, Mohler JL, Seigler HF, Besterman JM: Elevation of topoisomerase I-messenger RNA, protein and catalytic activity in human tumors: Demonstration of tumor type specificity and implications for cancer chemotherapy. Cancer Res 54: 539-546, 1994.
12. Potmesil M, Hsiang Y, Liu LF, Bank B, Grossberg H, Kirschenbaum S, Forlenzar TJ, Penziner A, Kanganis D, Knowles D, et al: Resistance of human leukemic and normal lymphocytes to drug-induced DNA cleavage and low levels of DNA topoisomerase II. Cancer Res 48: 3537-3543, 1988.
13. van der Zee AG, Hollema H, de Jong S, Boonstra H, Grouw A, Willemse PHB, Zilstra JG, de Vries GE: P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and malignant tumors of the ovary before and after Platinum/Cyclophosphamide chemotherapy. Cancer Res 51: 5915-5920, 1991.
14. Boothman DA, Wang M, Schea R, Burrows HL, Strickfaden S, Owens JK: Posttreatment exposure to camptothecin enhances the lethal effects of X-rays on radioresistant human malignant melanoma cells. Int J Rad Oncol Biol Phys 24: 938-948, 1992.
15. Ng CE, Bussey AM, Raaphorst GP: Sequence of treatment is important in the modification of camptothecin induced cell killing by hyperthermia. Int J Hyperthermia 12: 663-678, 1996.
16. Teicher BA, Holden SA, Khandakar V, Herman TS. Addition of a topoisomerase I inhibitor to trimodality [cisdiamminedichloroplatinum (II)/heat/radiation) in a murine tumour. J Cancer Res and Clin Oncol 119: 645-651, 1993.
17. Kampinga HH: Hyperthermia, thermotolerance and topoisomerase II inhibitors. Brit J Cancer 72: 333-338, 1995.
18. Ng CE, Bussey AM, MacDonald HA, Heller DP, Wilkins DE, Raaphorst GP: Cross sensitivity to x-radiation and type I and II DNA topoisomerase inhibitors in a range of human and rodent cell lines. Int J Oncology 7: 1179-1184, 1995.
19. Dancey J, Eisenhauer EA: Current perspectives on camptothecins in cancer treatment. Brit J Cancer 74: 327-338, 1996.
20. Chen AY, Liu L, Goldstein LJ and Ozols RF, editors: Mechanisms of resistance to topoisomerase inhibitors in Anticancer Drug Resistance: Advances in Molecular and Clinical Research. Kluwer Academic Press; 1994;
21. Beck WT, Cirtain MC, Danks MK, Felsted RL, Safa AR, Wolverton JS, Suttle DP, Trent JM: Pharmacological, molecular and cytogenetic analysis of 'atypical' multidrug resistant human leukemic cells. Cancer Res 47: 5455-5460, 1987.
22. Tanizawa A, Pommier Y: Topoisomcrasc I alteration in a camptothecin-resistant cell line derived from Chinese hamster DC3F cells in culture. Cancer Res 52: 1848-1854, 1992.
23. Andoh T, Ishii K, Suzuki Y, Ikegami Y, Kusunoki Y, Takemoto Y, Okada K: Characterization of a mammalian mutant with a camptothecin resistant DNA topoisomerase I. Proc Natl Acad Sci U.S.A. 84: 5565-5569, 1987.
24. Sugimoto Y, Tsukahara S, Oh-hara T, Liu L, Tsuruo T: Elevated expression of DNA topoisomerase II in camptothecin resistant human tumor cell lines. Cancer Res 50: 7962-7965, 1990.
25. Sorensen M, Sehested M, Jensen PB: Characterization of a human small cell lung cancer cell line resistant to the DNA topoisomerse I -directed drug topotecan. Brit J Cancer 72: 399-404, 1995.
26. Kotoh S, Naito S, Yokomizo A, Kumuzawa J, Asakuno K, Kohno K, Kuwano M: Increased expression of DNA topoisomerase I gene and collateral sensitivity to camptothecin in human cisplatin-resistant bladder cancer cells. Cancer Res 54: 3248-3252, 1994.
27. Samuels D, Shimizu Y, Shimizu N: Protein kinase C phosphorylates DNA topoisomerase I. FEBS Letter 259: 57-60, 1989.
28. Samuels D, Shimizu N: DNA topoisomerase I phosphorylation in murine fibroblasts treated with 12-O-tetradecanoylphorbol-13-acetate and in vitro by protein kinase C. J Biol Chem 267: 11156-11162, 1992.
29. Jongstra-Bilen J, Ittel ME, Niedergang C, et al. DNA topoisomerase I from calf thymus is inhibited in vitro by poly(ADP-ribosylation). Eur J Biochem 136: 391-396, 1983.
30. Kasid U, Halligan B, Liu L, et al: Poly(ADP-ribose)-mediated post-translational modification of chromatin-associated human topoisomerase I. Inhibitory effects on catalytic activity. J Biol Chem 264: 18687-18692, 1989.
31. Benedetti P, Fiorani P, Capuani L, Wang JC: Camptothecin resistance from a single mutation changing glycine 363 of human DNA topoisomerase I to cysteine. Cancer Res 53: 4343-4348, 1993.
32. Sugimoto Y, Tsukahara S, Oh-hara T, Isoe T, Tsuruo T: Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. Cancer Res 50: 6925-6930, 1990.
33. Tan KB, Mattern MR, Eng WK, McCabe FL, Johnson RK: Nonproductive rearrangment of DNA topoisomerase I and II Genes: Correlation with resistance to topoisomerase inhibitors. JNCI 81: 1732-1735, 1989.
34. McLeod HL, Keith WN: Variation in topoisomerase I gene copy number as a mechanism for intrinsic drug sensitivity. Brit J Cancer 74: 508-512, 1996.
35. Beidler DR, Cheng Y: Camptothecin Induction of a Time-and Concentration-Dependent Decrease of Topoisomerase I and Its Implication in Camptothecin Activity. Molecular Pharmacology 47: 907-914, 1995.
36. Lanza A, Tornaletti S, Stefanini M, Evans HH, Ricanati M, Giulia CB, Ricotti A, Pedrini M: The sensitivity to DNA topoisomerase inhibitors in L5178Y lymphoma strains is not related to a primary defect of DNA topoisomerases. Carcinogenesis 14: 1759-1763, 1993.
37. Goldwasser F, Bae I, Valenti M, Torres K, Pommier Y: Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute Anticancer screen. Cancer Res 55: 2116-2121, 1995.
38. Squires S, Ryan AJ, Strutt HL, Johnson RT: Hypersensitivity of Cockayne's syndrome cells to camptothecin is associated with the generation of abnormally high levels of double strand. Cancer Res 53: 2012-2019, 1993.
39. Ryan AJ, Squires S, Strutt HL, Johnson RT: Camptothecin cytotoxicity in mammalian cells is associated with the induction of persistent double strand breaks in replicating DNA. Nuc Acids Res 9: 3295-3300, 1991.
40. Yoshida A, Ueda T, Wano Y, Nakamura T: DNA damage and cell killing by camptothecin and its derivatives in human leukemia HL60 cells. Jap J Cancer Res 84: 566-573, 1993.
41. Takano H, Kohno K, Ono M, Uchida Y, Kuwano M: Increased phophorylation of DNA topoisomerase II in etoposide resistant mutants of human cancer KB cells. Cancer Res 51: 3951-3957, 1991.
42. Hannequin C, Giocanti N, Balosso J, Favaudon V: Interaction of ionizing radiation with the topoisomerase I poison Camptothecin in growing V-79 and HeLa cells. Cancer Res 54: 1720-1728, 1994.
43. Zanier R, De Salvia R, Fiore M, Degrassi F: Topoisomerase I activity and cellular response to radiation in Chinese hamster cells. Int J Rad Biol 70: 251-259, 1996.
44. Phillips RM, Clayton MRK: Plateau-phase cultures: an experimental model for identifying drugs which are bioactivated within the microenvironment of solid tumors. Brit J Cancer 75: 196-201, 1997.
45. Gupta M, Fujimori A, Pommier Y: Eukaryotic DNA topoisomerases I. Biochem Biophysic Acta 262: 1-14, 1995.
46. Pommier Y, Leteutre F, Fesen MR, Fujimori A, Bertrand R, Solary E, Kohlhagen G, Kohn KW: Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Inv 12: 530-542, 1994.
47. Chabert MG, Kopp PC, Bischoff PL, Mandel P: Cell culture of tumors alters endogenous poly(ADPR) polymerase expression and activity. Int J Cancer 53: 837-842, 1993.
48. Hsiang YH, Lihou MG, Liu LF: Arrest of replication forks by drug-stabilized topoisomerase I-DNA Cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 49: 5077-5082, 1989.
49. Del Bino G, Lassota P, Darzynkiewicz Z: The S-phase cytotoxicity of camptothecin. Exp Cell Res 193: 27-35, 1991.
50. Heck MMS, Hittelman WN, Earnshaw WC: Differential expression of DNA topoisomerase I and II during the eukaryotic cell cycle. PNAS, USA 85: 1086-1090, 1988.
51. O'Connor PM, Nieves-Neira W, Kerrigan D, Bertrand R, Golman J, Kahn KW, Pommier Y: S phase population analysis does not correlate with cytotoxicity of camptothecin and 10,11-methylene-dioxycamptothecin in human colon carcinoma HT-29 cells. Cancer Commun 3: 233-240, 1991.